William Rieflin
Chairman chez NGM BIOPHARMACEUTICALS, INC.
Fortune : 850 604 $ au 31/03/2024
Profil
William J.
Rieflin currently works at NGM Biopharmaceuticals, Inc., as Non-Executive Chairman from 2022, Rapt Therapeutics, Inc., as Chairman from 2019, Cumbre Pharmaceuticals, Inc., as Director, Kallyope, Inc., as Independent Non-Executive Director from 2016, Lyell Immunopharma, Inc., as Independent Director from 2020, and Lycia Therapeutics, Inc., as Director from 2020.
Mr. Rieflin also formerly worked at XenoPort, Inc., as Director from 2010 to 2016, Anacor Pharmaceuticals LLC, as Lead Independent Director from 2014 to 2016, Flexus Biosciences, Inc., as Director, AMSCO International, Inc., as Secretary & Vice President-Human Resources, Tularik, Inc., as CFO, Secretary & Executive VP-Administration from 1996 to 2004, American Hospital Supply Corp., as Head-Sales, and Sidley & Austin, as Associate.
Mr. Rieflin received his undergraduate degree from Cornell University, Masters Business Admin degree from The University of Chicago Booth School of Business, and graduate degree from Stanford Law School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RAPT THERAPEUTICS, INC.
0,27% | 28/03/2024 | 94 722 ( 0,27% ) | 850 604 $ | 31/03/2024 |
LYELL IMMUNOPHARMA, INC.
-.--% | 08/09/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de William Rieflin
| Sociétés | Poste | Début |
|---|---|---|
| NGM BIOPHARMACEUTICALS, INC. | Chairman | 01/09/2018 |
| RAPT THERAPEUTICS, INC. | Chairman | 01/06/2019 |
| LYELL IMMUNOPHARMA, INC. | Director/Board Member | 01/05/2020 |
Cumbre Pharmaceuticals, Inc.
 Cumbre Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cumbre Pharmaceuticals, Inc. discovers, develops, and markets anti-infective products for the treatment of serious and life-threatening infections, particularly caused by antibiotic resistant pathogens. Cumbre Pharmaceuticals was founded in 2001 and is headquartered in Dallas, TX | Director/Board Member | - |
Kallyope, Inc.
 Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | Director/Board Member | 27/10/2016 |
Lycia Therapeutics, Inc.
 Lycia Therapeutics, Inc. BiotechnologyHealth Technology Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA. | Director/Board Member | 01/01/2020 |
Anciens postes connus de William Rieflin
| Sociétés | Poste | Fin |
|---|---|---|
| XENOPORT, INC. | President | 26/08/2010 |
| ANACOR PHARMACEUTICALS INC | Director/Board Member | 24/06/2016 |
Flexus Biosciences, Inc.
 Flexus Biosciences, Inc. BiotechnologyHealth Technology Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA. | Director/Board Member | 01/01/2015 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░░░░░ ░░░░░ | ░░░░░ ░ ░░░░░░░░░ | - |
Formation de William Rieflin
| Cornell University | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
| Stanford Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| NGM BIOPHARMACEUTICALS, INC. | Health Technology |
| RAPT THERAPEUTICS, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
AMSCO International, Inc.
 AMSCO International, Inc. Medical SpecialtiesHealth Technology Part of STERIS Plc (Ireland), AMSCO International, Inc. makes infection control and decontamination products. The private company is based in Pittsburgh, PA. AMSCO International was acquired by STERIS Corp. on May 13, 1996 for $619.50 million. | Health Technology |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Cumbre Pharmaceuticals, Inc.
Cumbre Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cumbre Pharmaceuticals, Inc. discovers, develops, and markets anti-infective products for the treatment of serious and life-threatening infections, particularly caused by antibiotic resistant pathogens. Cumbre Pharmaceuticals was founded in 2001 and is headquartered in Dallas, TX | Health Technology |
| American Hospital Supply Corp. | Health Technology |
| Sidley & Austin | Commercial Services |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Flexus Biosciences, Inc.
Flexus Biosciences, Inc. BiotechnologyHealth Technology Flexus Biosciences, Inc. provides cancer therapeutics through innovative apps. It engages in leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression. The company was founded by Terry J. Rosen and Juan C. Jaen in 2013 and is headquartered in San Carlos, CA. | Health Technology |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | Health Services |
Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. BiotechnologyHealth Technology Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA. | Health Technology |
